Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:1566-1572, 2005
© 2005 by the American Diabetes Association, Inc.

Intensive Lifestyle Intervention or Metformin on Inflammation and Coagulation in Participants With Impaired Glucose Tolerance

The Diabetes Prevention Program Research Group

Increases in subclinical inflammation (C-reactive protein [CRP]) and impaired coagulation have been associated with increased obesity and insulin resistance. Only a few small studies have examined the effect of lifestyle changes, such as weight loss, increased physical activity, and insulin-sensitizing intervention on inflammation and coagulation. The Diabetes Prevention Program (DPP) clinical trial studied the effect of an intensive lifestyle intervention or metformin on progression to diabetes relative to placebo in 3,234 adults with impaired glucose tolerance. The effects of these interventions on CRP and fibrinogen at 12 months are examined in this report. Metformin reduced CRP in women compared with the placebo group. In men, the median changes in CRP from baseline to 1 year were –33% in the lifestyle group, –7% in the metformin group, and +5% in the placebo group. In women, the changes in CRP from baseline to follow-up were –29% in the lifestyle group, –14% in the metformin group, and 0% in the placebo group. In the lifestyle group weight loss rather than increased physical activity seems to account for most of the changes in CRP. Only modest reductions (although significant) were seen in fibrinogen levels in the lifestyle group relative to the metformin and placebo group. Lifestyle intervention reduced levels of nontraditional cardiovascular risk factors relative to both placebo and to a lesser degree to metformin.


Address correspondence and reprint requests to Diabetes Prevention Program Coordinating Center, The Biostatistics Center, George Washington University, 6110 Executive Blvd., Suite 750, Rockville, MD 20852. E-mail: dppmail{at}biostat.bsc.gwu.edu

Abbreviations: CRP, C-reactive peptide; DPP, Diabetes Prevention Program; HOMA-IR, homeostasis model assessment for insulin resistance; IGT, impaired glucose tolerance; IRAS, Insulin Resistance Atherosclerosis Study


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
J. L. Kitzmiller, L. Dang-Kilduff, and M. M. Taslimi
Gestational Diabetes After Delivery: Short-term management and long-term risks
Diabetes Care, July 1, 2007; 30(Supplement_2): S225 - S235.
[Full Text] [PDF]


Home page
Diabetes CareHome page
American Diabetes Association
Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association
Diabetes Care, January 1, 2007; 30(suppl_1): S48 - S65.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Libby and P. M. Ridker
Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
American Diabetes Association
Nutrition Recommendations and Interventions for Diabetes-2006: A position statement of the American Diabetes Association.
Diabetes Care, September 1, 2006; 29(9): 2140 - 2157.
[Full Text] [PDF]


Home page
DiabetesHome page
S. E. Kahn, B. Zinman, S. M. Haffner, M. C. O'Neill, B. G. Kravitz, D. Yu, M. I. Freed, W. H. Herman, R. R. Holman, N. P. Jones, et al.
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.
Diabetes, August 1, 2006; 55(8): 2357 - 2364.
[Abstract] [Full Text] [PDF]


Home page
Sci Aging Knowl EnvironHome page
J. A. Luchsinger
A Work in Progress: The Metabolic Syndrome
Sci. Aging Knowl. Environ., June 28, 2006; 2006(10): pe19 - pe19.
[Abstract] [Full Text]


Home page
Arch Intern MedHome page
M. Miller and S. Havas
The Role of Inflammation for Heart Disease Risk Cannot Be Determined by Correlations Between C-Reactive Protein and Risk Factors--Reply
Arch Intern Med, May 8, 2006; 166(9): 1040 - 1041.
[Full Text] [PDF]


Home page
CirculationHome page
F. B. Hu and M. J. Stampfer
Insulin Resistance and Hypertension: The Chicken-Egg Question Revisited
Circulation, September 20, 2005; 112(12): 1678 - 1680.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.